Background illustration for clinical trials search

Paid Clinical Trials Overland Park

Discover 722 paid clinical trials in Overland Park, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 722

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: Overland Park KS, Westwood KS, Kansas City MO,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for

Castration-Resistant Prostate Carcinoma,

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06632977

Phase2, Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for

Metastatic Salivary Gland Carcinoma,

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05408845

Phase2, Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

for

Cutaneous Melanoma, Stage II

Location: Overland Park KS, Westwood KS, Kansas City MO,

Sponsor: Melanoma and Skin Cancer Trials Limited

Sex: All

Age: 18+

Code: NCT03860883

Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for

Malignant Solid Neoplasm

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642611

Phase3, Recruiting

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for

Cardiotoxicity, HER2/Neu Positive,

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT03418961

Phase3, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase2, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase2, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for

Ovarian Carcinoma

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for

Carcinoma, Non-Small Cell Lung,

Location: Overland Park KS, Fairway KS, Kansas City KS,

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT04389632

Phase1, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for

Pancreatic Acinar Cell Carcinoma,

Location: Overland Park KS, Westwood KS, Kansas City KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

for

Metastatic Colorectal Adenocarcinoma,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06696768

Phase1, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Overland Park KS, Fairway KS, Westwood KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for

Breast Carcinoma, Colorectal Carcinoma,

Location: Overland Park KS, Westwood KS, Kansas City MO,

Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06418204

Recruiting

Paid Clinical Trials Overland Park

Filter results

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Interested in new trials?

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics